BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma (HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because most tumors acquire drug resistance over time. As the PI3K/AKT/mTOR signaling pathway is also activated abnormally in HCC,...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Am J Transl Res
Главные авторы: Li, Amin, Zhang, Rongbo, Zhang, Yinci, Liu, Xueke, Wang, Ruikai, Liu, Jiachang, Liu, Xinkuang, Xie, Yinghai, Cao, Weiya, Xu, Ruyue, Ma, Yongfang, Cai, Wenpeng, Wu, Binquan, Cai, Shuyu, Tang, Xiaolong
Формат: Artigo
Язык:Inglês
Опубликовано: e-Century Publishing Corporation 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6789287/
https://ncbi.nlm.nih.gov/pubmed/31632530
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы